cognitive cybersecurity intelligence

News and Analysis


Children’s hospitals prepare for surge in admissions amid shortage of RSV drug

The single-shot drug Nirsevimab, which can prevent the Respiratory Syncytial Virus (RSV) in infants, is short in supply. The Children’s Hospital Association says this will limit its impact this respiratory disease season. This drug, marketed as Beyfortus, cuts the risk of RSV-related hospitalization in infants by about 80% and, though supply constraints mean vulnerable infants are the priority, demand exceeds supply. The manufacturer AstraZeneca apparently underestimated the demand for the drug, despite its potential to prevent RSV.

Source: –

Subscribe to newsletter

Subscribe to HEAL Security Dispatch for the latest healthcare cybersecurity news and analysis.

More Posts